share_log

Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $61

Benzinga ·  Aug 8 17:58  · Ratings

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment